Skip to content
A Green Sign – Lifestyle
Author:
Attralus, Inc
Attralus Therapeutic Zamubafusp Alfa (AT-02) Receives U.S. FDA Orphan Drug Designation for the Treatment of AL Amyloidosis
June 4, 2026